Reports related to this article:
Project(s): View 1 related project in PECWeb
en
Written by Martin Lynch, European News Editor for Industrial Info (Galway, Ireland)--U.S. pharmaceutical company BioMarin Pharmaceutical (NYSE:BMRN) (San Rafael, California) has announced plans for a US$63 million expansion of its European manufacturing plant in Cork, Ireland.
The company wants to build a new four-storey laboratory building with a total floorspace of 37,000 square feet, which will include three laboratory rooms, freezer rooms, store rooms and a plant room to provide pharmaceutical research for the production plant. The investment in the Shanbally, Ringnaskiddy-based facility follows on from a previous $42 million investment in the site over four years that saw the construction of a state-of-the-art aseptic production facility. It allowed the company to create what it called "end-to-end" manufacturing by being able to manufacture, package and label BioMarin therapies for global distribution. The new project will let Biomarin increase production capacity for currently approved medicines and "create room for future growth". The Cork operation is the company's only manufacturing site outside of the U.S., and it employs more than 500 people in Ireland.
"This investment in our Cork facility reflects our ongoing commitment to enhancing our industry-leading global manufacturing capabilities and supporting the growth of our innovative medicines for our people living with rare conditions around the world," said BioMarin Senior Vice President Evelyn Marchany Garcia. "The Shanbally facility plays a crucial role in our global network, and this expansion emphasises our confidence in Ireland's skilled workforce and the strategic importance of this site to BioMarin's long-term success."
Michael Lohan, chief executive officer of Ireland's investment body, Industrial Development Agency (IDA), added: "As a global leader in the biopharmaceutical sector, BioMarin's ongoing investment in Ireland is a welcome endorsement of the country's position globally as a location of choice for biopharmaceuticals and a trailblazer in advancing healthcare solutions. By opening this new quality control and process development laboratory, BioMarin will create new opportunities for collaboration, talent development and growth, ensuring that the life sciences sector in Ireland continues to make an impact on patients' lives worldwide."
Ireland is the largest net exporter of pharmaceuticals in the European Union (EU), which account for more than 50% of all exports from the country. It is also the world's third largest exporter of pharmaceuticals, according to the UN International Trade Statistics database, accounting for 116 billion euro (US$122 billion) in annual exports. There are over 90 pharmaceutical companies operating in Ireland, employing more than 45,000 people. Industrial Info is tracking 142 Irish projects worth more than US$7 billion in investment. Subscribers to Industrial Info's Global Market Intelligence (GMI) Project Database can click here for the reports.
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).
The company wants to build a new four-storey laboratory building with a total floorspace of 37,000 square feet, which will include three laboratory rooms, freezer rooms, store rooms and a plant room to provide pharmaceutical research for the production plant. The investment in the Shanbally, Ringnaskiddy-based facility follows on from a previous $42 million investment in the site over four years that saw the construction of a state-of-the-art aseptic production facility. It allowed the company to create what it called "end-to-end" manufacturing by being able to manufacture, package and label BioMarin therapies for global distribution. The new project will let Biomarin increase production capacity for currently approved medicines and "create room for future growth". The Cork operation is the company's only manufacturing site outside of the U.S., and it employs more than 500 people in Ireland.
"This investment in our Cork facility reflects our ongoing commitment to enhancing our industry-leading global manufacturing capabilities and supporting the growth of our innovative medicines for our people living with rare conditions around the world," said BioMarin Senior Vice President Evelyn Marchany Garcia. "The Shanbally facility plays a crucial role in our global network, and this expansion emphasises our confidence in Ireland's skilled workforce and the strategic importance of this site to BioMarin's long-term success."
Michael Lohan, chief executive officer of Ireland's investment body, Industrial Development Agency (IDA), added: "As a global leader in the biopharmaceutical sector, BioMarin's ongoing investment in Ireland is a welcome endorsement of the country's position globally as a location of choice for biopharmaceuticals and a trailblazer in advancing healthcare solutions. By opening this new quality control and process development laboratory, BioMarin will create new opportunities for collaboration, talent development and growth, ensuring that the life sciences sector in Ireland continues to make an impact on patients' lives worldwide."
Ireland is the largest net exporter of pharmaceuticals in the European Union (EU), which account for more than 50% of all exports from the country. It is also the world's third largest exporter of pharmaceuticals, according to the UN International Trade Statistics database, accounting for 116 billion euro (US$122 billion) in annual exports. There are over 90 pharmaceutical companies operating in Ireland, employing more than 45,000 people. Industrial Info is tracking 142 Irish projects worth more than US$7 billion in investment. Subscribers to Industrial Info's Global Market Intelligence (GMI) Project Database can click here for the reports.
Industrial Info Resources (IIR) is the leading provider of industrial market intelligence. Since 1983, IIR has provided comprehensive research, news and analysis on the industrial process, manufacturing and energy related industries. IIR's Global Market Intelligence (GMI) helps companies identify and pursue trends across multiple markets with access to real, qualified and validated plant and project opportunities. Across the world, IIR is tracking over 200,000 current and future projects worth $17.8 Trillion (USD).
